A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection

HIV Infections Clinical Trial

Official title:

A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00000652
• Other study ID #: ACTG 176
• Secondary ID: NCI 91 C-09
• Status: Completed
• Phase: Phase 1
• First received: November 2, 1999
• Last updated: October 31, 2012
• Est. completion date: November 1995

Study information

• Verified date: October 2012
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

To assess the safety and tolerance of the combination of zidovudine (AZT) and didanosine (ddI) in children with HIV infection.

New approaches to using available agents may provide increased or improved treatment options for AIDS. Combination therapy is expected to play a major role in improving survival and quality of life for HIV-infected individuals. AZT and ddI are two agents that have been most extensively evaluated and for which the evidence for antiretroviral effectiveness is strongest.

Description:

New approaches to using available agents may provide increased or improved treatment options for AIDS. Combination therapy is expected to play a major role in improving survival and quality of life for HIV-infected individuals. AZT and ddI are two agents that have been most extensively evaluated and for which the evidence for antiretroviral effectiveness is strongest.

Patients take AZT and ddI on an empty stomach; ddI is taken 2 minutes after taking antacid. Part A patients receive AZT plus ddI each at ranging doses. Patients in part B may receive a higher dose of ddI than patients in part A. The first patients enrolled are given the lowest dose. Subsequent patients receive increasingly higher doses until a dose limiting toxicity occurs.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 85
• Est. completion date: November 1995
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 3 Months to 18 Years

Eligibility

Inclusion Criteria

Concurrent Medication:

Allowed:

• Corticosteroids for treatment of lymphocytic interstitial pneumonitis.

Concurrent Treatment:

Allowed:

• Intravenous hyperalimentation.

Patients must have the following:

• P-2 class symptomatic HIV infection as defined by CDC OR who are asymptomatic but whose total CD4 cell count is < 500 cells/mm3.

• Freedom from significant active opportunistic or other infection requiring specific therapy.

Part B patients:

• Prior treatment with zidovudine (AZT) that was discontinued because of hematologic toxicity.

• Availability of a parent or legal guardian who is sufficiently reliable to give informed consent and follow necessary study procedures including administration of medications and return for follow-up visits.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

• Critically ill, clinically unstable, or receiving drug therapy for an opportunistic or other infection.

• History of acute or chronic pancreatitis.

Patients with the following are excluded:

• Critically ill, clinically unstable, or receiving drug therapy for an opportunistic or other infection.

• History of acute or chronic pancreatitis.

Prior Medication:

Excluded:

• Antiretroviral or other antiviral agent within 14 days of entry into study.

• Immunomodulating agents, cytolytic chemotherapeutic agents, corticosteroids within 30 days (except for lymphocytic interstitial pneumonitis).

Part A patients:

• Zidovudine (AZT) or didanosine (ddI).

Part B patients:

• Didanosine (ddI).

Prior Treatment:

Excluded:

• Radiation therapy within 30 days.

• Intravenous immunoglobulin preparations within 14 days of entry into study.

Study Design

Intervention Model: Parallel Assignment, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Acquired Immunodeficiency Syndrome
• HIV Infections
• Infection

Intervention

Drug:
• Zidovudine

• Didanosine

Locations

Country	Name	City	State
United States	Children's Hosp of Los Angeles/UCLA Med Ctr	Los Angeles	California

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Mueller BU, Pizzo PA, Farley M, Husson RN, Goldsmith J, Kovacs A, Woods L, Ono J, Church JA, Brouwers P, et al. Pharmacokinetic evaluation of the combination of zidovudine and didanosine in children with human immunodeficiency virus infection. J Pediatr. 1994 Jul;125(1):142-6. — View Citation

External Links

•   Click here for more information about Didanosine
•   Click here for more information about Zidovudine